#United States #Boston #Pharmacovigilance #ArisGlobal #MedDRA Coding Agent

ArisGlobal's Groundbreaking Achievement

On October 23, 2025, ArisGlobal, a renowned tech company specializing in AI-driven solutions for the life sciences sector, proudly announced its reception of the prestigious Frost & Sullivan's 2025 Global New Product Innovation Recognition. This accolade highlights their innovative MedDRA Coding Agent, which is pioneering agentic AI in the realm of pharmacovigilance—an industry first.

The MedDRA Coding Agent was launched in April 2025 and quickly made waves within the market. This groundbreaking solution leverages advanced agentic AI capabilities to replicate human-level judgment in medical coding. By doing so, it overcomes the limitations of traditional static and rule-based systems. Unlike previous automated tools, this agent dynamically interprets clinical language, judiciously selects reasoning pathways, and improves continually through feedback from reviewers, thereby enhancing both accuracy and transparency.

Key Features of the MedDRA Coding Agent

1. Contextual Understanding: This AI distinguishes itself by interpreting clinical language far beyond mere keywords, capturing the meaning and intent behind the terms used.
2. Real-Time Learning: The agent adapts immediately from reviewer corrections and the evolving MedDRA terminology, continually enhancing its coding effectiveness.
3. Transparent Decision-Making: It provides clear reasoning for its coding choices, ensuring adherence to regulatory standards through its explainable and auditable processes.
4. Global Integration Ready: Built to support multinational operations, it meets various integration and validation demands across markets.
5. Adaptive Collaboration: The system intelligently prioritizes escalated cases, offering ranked coding options with rational explanations instead of flooding users with unnecessary noise.

The implementation of this leading-edge system has led to significant operational efficiency gains, reducing the manual workload for coding tasks while simultaneously improving consistency and regulatory compliance across global teams.

In its assessment, Frost & Sullivan remarked on ArisGlobal's exceptional innovation, stating, "ArisGlobal is truly revolutionizing pharmacovigilance through intelligent, context-aware systems that yield quantifiable operational and compliance advancements." Norazah Bachok, a research analyst at Frost & Sullivan, emphasized the agent's ability to deliver efficiency gains of up to 80%, which greatly lightens the load for reviewers while maintaining high accuracy standards.

Jason Bryant, Senior Vice President of Product Management at ArisGlobal, further elaborated on the development, saying, "The MedDRA Coding Agent is a significant advancement in the automation landscape of pharmacovigilance. By blending the cognitive sophistication of agentic AI with the established strengths of LifeSphere NavaX, we are transforming intricate coding processes into smart workflows that are both effective and efficient at scale. This innovation reflects our commitment to enhancing automation in the Safety and Regulatory ecosystem, and we plan to continue this momentum by introducing additional agents in the future."

Frost & Sullivan's Best Practices Recognition is awarded only to those companies demonstrating superior performance and innovation within their industries. The New Product Innovation Recognition is particularly distinctive, as it identifies organizations that exhibit visionary strategies, market-leading success, and unparalleled customer service. ArisGlobal excelled in Frost & Sullivan's stringent evaluation, aligning its strategies with the changing demands of the market while showcasing operational excellence. This honor reflects not just ArisGlobal's innovative prowess but also its significant contribution to the landscape of customer value and industry performance standards.

About ArisGlobal

Based in the United States, ArisGlobal is at the vanguard of AI-driven technology in life sciences. Its flagship product, LifeSphere®, serves as the foundation for the company’s relentless pursuit of innovation in bringing new therapeutic breakthroughs to market. With regional offices extending across Europe, India, Japan, and China, ArisGlobal is poised to reshape the way leading life sciences companies operate and innovate. Follow them for updates on LinkedIn and visit their website at www.arisglobal.com for more information.